Predictive value of tumor mutation burden (TMB) with targeted next-generation sequencing in immunocheckpoint inhibitors for non-small cell lung cancer (NSCLC)

Background: To evaluate the clinical predictive value of tumor mutation burden (TMB) for immune checkpoint inhibitor (ICI) therapy in patients with non-small cell lung cancer (NSCLC). Method: As of 15 February 2020, PubMed, PMC and EMBASE databases as well as the American society of clinical oncolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Xiaoting, Zhang, Yujian, Wang, Shan, Yu, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738995/
https://www.ncbi.nlm.nih.gov/pubmed/33391454
http://dx.doi.org/10.7150/jca.48105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738995/
https://www.ncbi.nlm.nih.gov/pubmed/33391454
http://dx.doi.org/10.7150/jca.48105

Ejemplares similares